{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:22:42Z","timestamp":1790101362110,"version":"4.0.1"},"reference-count":55,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ackdjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Chronic Kidney Disease"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1053\/j.ackd.2022.03.004","type":"journal-article","created":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T19:33:17Z","timestamp":1657308797000},"page":"141-148.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Sickle Cell Disease and Kidney"],"prefix":"10.1053","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8783-913X","authenticated-orcid":false,"given":"Pooja","family":"Amarapurkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0521-9306","authenticated-orcid":false,"given":"Levard","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Navarrete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8583-0526","authenticated-orcid":false,"given":"Fuad","family":"El Rassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.ackd.2022.03.004_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrdp.2018.10","article-title":"Sickle cell disease","volume":"4","author":"Kato","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"16","key":"10.1053\/j.ackd.2022.03.004_bib2","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1056\/NEJMra1510865","article-title":"Sickle cell disease","volume":"376","author":"Piel","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.ackd.2022.03.004_bib3","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1172\/JCI30920","article-title":"Sickle cell disease: old discoveries, new concepts, and future promise","volume":"117","author":"Frenette","year":"2007","journal-title":"J Clin Invest"},{"issue":"6 Pt 2","key":"10.1053\/j.ackd.2022.03.004_bib4","first-page":"F1166","article-title":"Differential regulation of renal regional blood flow by endothelin-1","volume":"271","author":"Gurbanov","year":"1996","journal-title":"Am J Physiol"},{"issue":"3","key":"10.1053\/j.ackd.2022.03.004_bib5","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0002-9440(10)64037-0","article-title":"Oxidative stress and induction of heme oxygenase-1 in the kidney in sickle cell disease","volume":"158","author":"Nath","year":"2001","journal-title":"Am J Pathol"},{"issue":"12","key":"10.1053\/j.ackd.2022.03.004_bib6","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1080\/17474086.2017.1395279","article-title":"The spectrum of sickle hemoglobin-related nephropathy: from sickle cell disease to sickle trait","volume":"10","author":"Naik","year":"2017","journal-title":"Expert Rev Hematol"},{"issue":"3","key":"10.1053\/j.ackd.2022.03.004_bib7","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1600-0609.2010.01471.x","article-title":"Urinary albumin excretion is associated with pulmonary hypertension in sickle cell disease: potential role of soluble fms-like tyrosine kinase-1","volume":"85","author":"Ataga","year":"2010","journal-title":"Eur J Haematol"},{"issue":"3","key":"10.1053\/j.ackd.2022.03.004_bib8","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/nrneph.2015.8","article-title":"Sickle cell disease: renal manifestations and mechanisms","volume":"11","author":"Nath","year":"2015","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"10.1053\/j.ackd.2022.03.004_bib9","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2215\/CJN.03940415","article-title":"Kidney disease among patients with sickle cell disease, hemoglobin SS and SC","volume":"11","author":"Drawz","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"10.1053\/j.ackd.2022.03.004_bib10","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1681\/ASN.2002010084","article-title":"Glomerular involvement in adults with sickle cell hemoglobinopathies: prevalence and clinical correlates of progressive renal failure","volume":"17","author":"Guasch","year":"2006","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ackd.2022.03.004_bib11","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1681\/ASN.V1051014","article-title":"Evidence that microdeletions in the alpha globin gene protect against the development of sickle cell glomerulopathy in humans","volume":"10","author":"Guasch","year":"1999","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ackd.2022.03.004_bib12","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.3324\/haematol.2016.154153","article-title":"APOL1, \u03b1-thalassemia, and BCL11A variants as a genetic risk profile for progression of chronic kidney disease in sickle cell anemia","volume":"102","author":"Saraf","year":"2017","journal-title":"Haematologica"},{"issue":"3","key":"10.1053\/j.ackd.2022.03.004_bib13","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1365-2141.2011.08832.x","article-title":"MYH9 and APOL1 are both associated with sickle cell disease nephropathy","volume":"155","author":"Ashley-Koch","year":"2011","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1053\/j.ackd.2022.03.004_bib14","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ajh.20800","article-title":"Estimated glomerular filtration rate in sickle cell anemia is associated with polymorphisms of bone morphogenetic protein receptor 1B","volume":"82","author":"Nolan","year":"2007","journal-title":"Am J Hematol"},{"issue":"7644","key":"10.1053\/j.ackd.2022.03.004_bib15","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0140-6736(70)90836-6","article-title":"Nature of concentrating defect in sickle-cell nephropathy","volume":"1","author":"Statius van Eps","year":"1970","journal-title":"Microradioangiographic Studies Lancet"},{"issue":"3","key":"10.1053\/j.ackd.2022.03.004_bib16","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/0009-8981(67)90222-7","article-title":"The influence of red blood cell transfusions on the hyposthenuria and renal hemodynamics of sickle cell anemia","volume":"17","author":"Statius van Eps","year":"1967","journal-title":"Clin Chim Acta"},{"issue":"3","key":"10.1053\/j.ackd.2022.03.004_bib17","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1365-2141.2011.08853.x","article-title":"Sickle cell nephropathy - a practical approach","volume":"155","author":"Sharpe","year":"2011","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1053\/j.ackd.2022.03.004_bib18","doi-asserted-by":"crossref","first-page":"648","DOI":"10.2215\/CJN.09790913","article-title":"Prevalence and correlates of metabolic acidosis among patients with homozygous sickle cell disease","volume":"9","author":"Maurel","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ackd.2022.03.004_bib19","doi-asserted-by":"crossref","first-page":"310","DOI":"10.7326\/0003-4819-90-3-310","article-title":"Impaired renal tubular potassium secretion in sickle cell disease","volume":"90","author":"DeFronzo","year":"1979","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1053\/j.ackd.2022.03.004_bib20","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/0002-9343(82)90809-9","article-title":"Hyperkalemic hyperchloremic metabolic acidosis in sickle cell hemoglobinopathies","volume":"72","author":"Batlle","year":"1982","journal-title":"Am J Med"},{"issue":"1","key":"10.1053\/j.ackd.2022.03.004_bib21","doi-asserted-by":"crossref","first-page":"16","DOI":"10.2215\/CJN.07830719","article-title":"Tubular acidification defect in adults with sickle cell disease","volume":"15","author":"Cazenave","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"10.1053\/j.ackd.2022.03.004_bib22","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/sj.ki.5002060","article-title":"Sickle cell trait and gross hematuria","volume":"71","author":"Kiryluk","year":"2007","journal-title":"Kidney Int"},{"issue":"24","key":"10.1053\/j.ackd.2022.03.004_bib23","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1182\/blood-2014-02-557439","article-title":"How I treat renal complications in sickle cell disease","volume":"123","author":"Sharpe","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.ackd.2022.03.004_bib24","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0002-9343(96)00407-X","article-title":"Natural history of blood pressure in sickle cell disease: risks for stroke and death associated with relative hypertension in sickle cell anemia","volume":"102","author":"Pegelow","year":"1997","journal-title":"Am J Med"},{"issue":"1","key":"10.1053\/j.ackd.2022.03.004_bib25","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jpeds.2009.06.060","article-title":"Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial","volume":"156","author":"Ware","year":"2010","journal-title":"J Pediatr"},{"issue":"2","key":"10.1053\/j.ackd.2022.03.004_bib26","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/ajh.23365","article-title":"Hydroxyurea treatment decreases glomerular hyperfiltration in children with sickle cell anemia","volume":"88","author":"Aygun","year":"2013","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1053\/j.ackd.2022.03.004_bib27","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1053\/j.ajkd.2018.12.027","article-title":"Progressive decline in estimated GFR in patients with sickle cell disease: an Observational cohort study","volume":"74","author":"Derebail","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.ackd.2022.03.004_bib28","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/MD.0b013e3181ca59b6","article-title":"Glomerular lesions in patients with sickle cell disease","volume":"89","author":"Maigne","year":"2010","journal-title":"Medicine (Baltimore)"},{"issue":"7","key":"10.1053\/j.ackd.2022.03.004_bib29","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/bloodadvances.2019001378","article-title":"Progression of albuminuria in patients with sickle cell anemia: a multicenter, longitudinal study","volume":"4","author":"Niss","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"10.1053\/j.ackd.2022.03.004_bib30","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1365-2141.2009.08062.x","article-title":"Acute human parvovirus B19 infection and nephrotic syndrome in patients with sickle cell disease","volume":"149","author":"Quek","year":"2010","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1053\/j.ackd.2022.03.004_bib31","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/ajh.23762","article-title":"The glomerulopathy of sickle cell disease","volume":"89","author":"Ataga","year":"2014","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1053\/j.ackd.2022.03.004_bib32","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1097\/01.JIM.0000446836.75352.72","article-title":"Prevalence and progression of chronic kidney disease in adult patients with sickle cell disease","volume":"62","author":"Gosmanova","year":"2014","journal-title":"J Investig Med"},{"issue":"7","key":"10.1053\/j.ackd.2022.03.004_bib33","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2016101086","article-title":"Sickle cell trait and the risk of ESRD in blacks","volume":"28","author":"Naik","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ackd.2022.03.004_bib34","doi-asserted-by":"crossref","first-page":"9","DOI":"10.5414\/CNP58009","article-title":"Sickle cell nephropathy at end-stage renal disease in the United States: patient characteristics and survival","volume":"58","author":"Abbott","year":"2002","journal-title":"Clin Nephrol"},{"issue":"3","key":"10.1053\/j.ackd.2022.03.004_bib35","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/bjh.12024","article-title":"High one year mortality in adults with sickle cell disease and end-stage renal disease","volume":"159","author":"McClellan","year":"2012","journal-title":"Br J Haematol"},{"issue":"17","key":"10.1053\/j.ackd.2022.03.004_bib36","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1182\/blood-2009-07-233700","article-title":"Improved survival of children and adolescents with sickle cell disease","volume":"115","author":"Quinn","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.ackd.2022.03.004_bib37","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2215\/CJN.02720320","article-title":"Mortality and access to kidney transplantation in patients with sickle cell disease-associated kidney failure","volume":"16","author":"Bae","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"10.1053\/j.ackd.2022.03.004_bib38","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1093\/ndt\/gfq083","article-title":"Acute kidney injury in sickle patients with painful crisis or acute chest syndrome and its relation to pulmonary hypertension","volume":"25","author":"Audard","year":"2010","journal-title":"Nephrol Dial Transpl"},{"issue":"1","key":"10.1053\/j.ackd.2022.03.004_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1523-1755.2000.00806.x","article-title":"Renal abnormalities in sickle cell disease","volume":"57","author":"Pham","year":"2000","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.ackd.2022.03.004_bib40","doi-asserted-by":"crossref","first-page":"348","DOI":"10.2215\/CJN.06960520","article-title":"Acute kidney injury among Black patients with sickle cell trait and sickle cell disease","volume":"16","author":"Olaniran","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"10.1053\/j.ackd.2022.03.004_bib41","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1097\/CCM.0000000000000316","article-title":"Outcomes of adult patients with sickle cell disease admitted to the ICU: a case series","volume":"42","author":"Cecchini","year":"2014","journal-title":"Crit Care Med"},{"issue":"10","key":"10.1053\/j.ackd.2022.03.004_bib42","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/jama.2014.10517","article-title":"Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members [published correction appears in JAMA. 2014 Nov 12;312(18):1932] [published correction appears in JAMA. 2015 Feb 17;313(7):729]","volume":"312","author":"Yawn","year":"2014","journal-title":"JAMA"},{"issue":"11","key":"10.1053\/j.ackd.2022.03.004_bib44","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/sj.ki.5000248","article-title":"Early markers of renal dysfunction in patients with sickle cell\/beta-thalassemia","volume":"69","author":"Voskaridou","year":"2006","journal-title":"Kidney Int"},{"issue":"12","key":"10.1053\/j.ackd.2022.03.004_bib45","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1007\/s00277-019-03813-9","article-title":"Non-invasive urinary biomarkers of renal function in sickle cell disease: an overview","volume":"98","author":"Laurentino","year":"2019","journal-title":"Ann Hematol"},{"issue":"Supplement 1","key":"10.1053\/j.ackd.2022.03.004_bib46","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2020-139500","article-title":"Use of Multiple urinary biomarkers for early detection of chronic kidney disease in sickle cell anemia patients","volume":"136","author":"Castro-Sesquen","year":"2020","journal-title":"Blood"},{"issue":"23","key":"10.1053\/j.ackd.2022.03.004_bib47","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1182\/bloodadvances.2019000916","article-title":"American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease","volume":"3","author":"Liem","year":"2019","journal-title":"Blood Adv"},{"issue":"9","key":"10.1053\/j.ackd.2022.03.004_bib48","doi-asserted-by":"crossref","first-page":"E520","DOI":"10.1002\/ajh.24810","article-title":"Losartan for the nephropathy of sickle cell anemia: a phase-2, multicenter trial","volume":"92","author":"Quinn","year":"2017","journal-title":"Am J Hematol"},{"issue":"14","key":"10.1053\/j.ackd.2022.03.004_bib50","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1182\/bloodadvances.2020001469","article-title":"Curative vs targeted therapy for SCD: does it make more sense to address the root cause than target downstream events?","volume":"4","author":"Telen","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"10.1053\/j.ackd.2022.03.004_bib53","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.hoc.2019.01.014","article-title":"Sickle cell disease: monitoring, Current treatment, and Therapeutics under development","volume":"33","author":"Hoppe","year":"2019","journal-title":"Hematol Oncol Clin North Am"},{"issue":"1","key":"10.1053\/j.ackd.2022.03.004_bib54","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/sdi.12403","article-title":"Management of the dialysis patient with sickle cell disease","volume":"29","author":"Boyle","year":"2016","journal-title":"Semin Dial"},{"issue":"2","key":"10.1053\/j.ackd.2022.03.004_bib55","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/00007890-199901270-00018","article-title":"Renal transplantation in end-stage sickle cell nephropathy","volume":"67","author":"Ojo","year":"1999","journal-title":"Transplantation"},{"key":"10.1053\/j.ackd.2022.03.004_bib56","first-page":"614610","article-title":"Outcome and challenges of kidney transplant in patients with sickle cell disease","volume":"2013","author":"Okafor","year":"2013","journal-title":"J Transpl"},{"issue":"1","key":"10.1053\/j.ackd.2022.03.004_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.6002\/ect.2011.0098","article-title":"Sickle cell and renal transplant: a national survey and literature review","volume":"10","author":"Nath","year":"2012","journal-title":"Exp Clin Transpl"},{"issue":"8","key":"10.1053\/j.ackd.2022.03.004_bib58","doi-asserted-by":"crossref","first-page":"e0236998","DOI":"10.1371\/journal.pone.0236998","article-title":"Outcomes following kidney transplantation in patients with sickle cell disease: the impact of automated exchange blood transfusion","volume":"15","author":"Willis","year":"2020","journal-title":"PLoS One"},{"issue":"5","key":"10.1053\/j.ackd.2022.03.004_bib59","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1182\/bloodadvances.2017012500","article-title":"Toward dual hematopoietic stem-cell transplantation and solid-organ transplantation for sickle-cell disease","volume":"2","author":"Hosoya","year":"2018","journal-title":"Blood Adv"}],"container-title":["Advances in Chronic Kidney Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559522000532?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559522000532?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:05:21Z","timestamp":1761548721000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1548559522000532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S1548559522000532"],"URL":"https:\/\/doi.org\/10.1053\/j.ackd.2022.03.004","relation":{},"ISSN":["1548-5595"],"issn-type":[{"value":"1548-5595","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sickle Cell Disease and Kidney","name":"articletitle","label":"Article Title"},{"value":"Advances in Chronic Kidney Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ackd.2022.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the National Kidney Foundation, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}